Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
The causation theory linking GLP-1 RAs to injuries such as NAION, gastroparesis, and biliary diseases is supported by adverse event reports, scientific investigations, and legal findings. The FDA has issued warnings about gastrointestinal risks, including ileus, which suggest a plausible causal relationship. Scientific and medical literature indicates that these drugs may contribute to vascular and gastrointestinal injuries, with diagnosis based on clinical, imaging, and laboratory criteria.
3,848
Pending actions
3,882
Total actions filed
Active
Status
02/02/2024
Established
Filing deadline
Specific filing deadlines are not publicly detailed but are governed by federal rules and court orders. Expert discovery deadlines are set for March 2026, with bellwether trials expected to start shortly thereafter.
Who qualifies
Plaintiffs must demonstrate use of the drug for a minimum duration prior to injury onset, with documentation of dosage within therapeutic ranges. Injuries must be diagnosed through objective medical testing, such as gastric emptying studies for gastroparesis, ophthalmologic examinations for NAION, and imaging/laboratory tests for biliary and gallbladder diseases. The injury must have occurred within a timeframe consistent with drug exposure, typically months to years, as supported by medical records and expert testimony.
Products involved
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Rybelsus (semaglutide)
- Mounjaro (tirzepatide)
- Trulicity (dulaglutide)
- Saxenda (liraglutide)
Alleged injuries
- NAION (Non-Arteritic Ischemic Optic Neuropathy)
- Gastroparesis
- Biliary and Gallbladder Diseases
Bellwether trials
Bellwether trials are scheduled to commence in mid-2026, with expert discovery concluding in March 2026. Procedural orders from the court indicate active management of pretrial activities, with ongoing case developments and procedural milestones.
Lead counsel
- Paul Pennock (Morgan & Morgan, P.A.)
- Parvin Aminolroaya (Seeger Weiss, LLP)
- Jonathan Orent (Motley Rice)
- Susen Law Group
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
